21 jun: Odico A/S justerer forventningerne til årets resultat.
21 jun: Anmodning om suspension af handel i SKAGENs fonde
21-06-2019 09:00:00

Zealand Pharma introduces new website to support people living with short bowel syndrome

Press release – No. 15 / 2019

Zealand Pharma introduces new website to support people living with short bowel syndrome

  • LivingWithSBS.com is a new website with information about short bowel syndrome, drawing from experiences shared by SBS patients to support others living with the disease

     

  • Zealand Pharma is dedicated to supporting people living with SBS by also developing next generation peptide therapeutics and working to continuously improve the standard of care

Copenhagen, June 21, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today launched a new website dedicated to supporting people with short bowel syndrome (SBS).

The website leverages the stories and experiences of several patients and their families, as a way to focus on key aspects of living with SBS. Elements of personal insight, what to expect from available medical care and inspiration for achieving intestinal rehabilitation are intended to help SBS patients improve management of the disease for a better everyday quality of life.

Medical contributors includes Professor David F. Mercer, MD, PhD, University of Nebraska Medical Center (Omaha), and Professor Kishore R. Iyer, MBBS, FRCS, the Mount Sinai Hospital (New York). These field experts provide educational disease information, including explanation of the circumstances arising from short bowel disease and available treatment options.

“The rarity of SBS makes it an ‘orphan disease’. Medical expertise in SBS is in short supply, and desperate patients and their families often end up going from pillar to post, searching for expert teams. Our aim is to empower patients to talk with their medical teams, to continuously improve the treatment and management options for living with short bowel syndrome,” said Professor Kishore R. Iyer, MBBS, FRCS, from the Mount Sinai Hospital in New York. “When someone has SBS, their entire family lives and copes with the disease. We want to extend resources and support to this entire community, and LivingWithSBS.com can help as a launch point.”

“Launching the new website, LivingWithSBS.com, is an ideal way to connect members of the short bowel syndrome community,” said Michael Hall, Senior Vice President of Clinical and Medical Affairs at Zealand Pharma. “The personal stories shared by people living with SBS reveal the extreme burdens of the disease, while also offering support and encouragement for other patients and their families to seek optimal management and treatment.”

Visit LivingWithSBS.com to learn more about short bowel syndrome, and hear the stories from several patients and their families who successfully manage the disease in everyday life.

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

About short bowel syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
03 jun - 
Zealand Pharma/Bryan Garnier: Løfter kursmål til 180 kr..
24 maj - 
Zealand Pharma/SHB: Kursmålet løftes mens anbefalingen ..
22 maj - 
Onsdagens aktier: Overbevisende regnskab sendte Simcorp..
Relateret debat
12 jul - 
Og ja, først skal den tidligere top i kurs 169 b..
12 jul - 
Investtech d.d.: "Videre stigning til 190 eller mere er..
12 jul - 
Om ikke andet så er CFO-annonceringen og nø..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 jul
ZEAL
Ja, så vafventer vi næste trin i 160
3
12 jul
ZEAL
Griner kommer ikke i 100 mere og Velo kommer ikke i 1 kr igen.. så meget godt du ikke var med😅
2
12 jul
ZEAL
Og ja, først skal den tidligere top i kurs 169 brydes ...
1
12 jul
ZEAL
Investtech d.d.: "Videre stigning til 190 eller mere er signaleret."   Men derfor kan ZP sagtens fal..
1
12 jul
ZEAL
Om ikke andet så er CFO-annonceringen og nødpen-partneraftalen tætter på!
1
12 jul
ZEAL
Dejlig stigning, men man skal aldrig sige aldrig,  sidst den var heroppe, troede man kurs 80 var umu..
1
12 jul
ZEAL
Jeg ærgrer mig over at jeg ikke har været med på stigningen. Havde ikke drømt om at kursen kunne sti..
1
12 jul
ZEAL
Det er godt at se at 150 er brudt klart!
1
12 jul
ZEAL
Kurs 151, steget 4,7 point i dag.   Er der nyt, vi små ikke ved endnu?
1
09 jul
ZEAL
Der er vel ikke kommet noget negativt, men heller ikke noget positivt, ramte dobbelttop i 150, lidt ..
1

Kina fremviser sløjeste vækst i årtier midt i handelskrig

15-07-2019 13:28:01
Kineserne må vænne sig til, at økonomien ikke længere buldrer afsted.Tocifrede vækstrater er fortid, og det bliver mandag understreget af nye tal for landets økonomi.I andet kvartal voksede Kinas bruttonationalprodukt med 6,2 procent. Det er den sløjeste fremgang i omkring tre årtier, skriver nyhedsbureauet Reuters.De økonomiske data fra Kina er under stor bevågenhed på grund af den handelskonflik..

Positivt Europa fortsætter optimismen fra sidste uges rekorddage i USA

Relaterede nyheder
15-07-2019 13:25:18
De europæiske markeder ligger i dagens handel i et lille plus. Det belgiske BEL20-indeks er i spidsen med en stigning på 0,8 pct. mens det tyske Dax-indeks ligeledes har en god dag og handles 0,3 pct. op. Det hjemlige C25-indeks ligger akkurat over nullet med en stigning på 0,12 pct.Det belgiske biotekselskab Galapagos NV tager førstepladsen i Europa med en stigning på 16,31 pct. Stigningen kommer..

Estimater for Topdanmarks Q2-regnskab – Præmievækst og færre brandskader giver fremgang

15-07-2019 12:46:24
Forsikringskoncernen Topdanmark ventes at følge trenden fra konkurrenten Trygs regnskab tidligere i juli og vise fremgang i andet kvartal. Sydbanks analytiker Mikkel Emil Jensen venter, at sundt præmiemomentum og færre brandskader vil sikre resultatfremgang hos Topdanmark.Analytikere, som har leveret estimater til Topdanmark, venter en vækst i præmieindtægterne på lige over 2,5 pct. i kvartalet og..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Ugens regnskaber og nøgletal – Danske Bank-regnskab, Kinesisk BNP & FED-taler
2
Aktier/tendens: Genmab i rampelyset i ventet grøn start
3
Nordea/Jyske Bank: Sænker kursmål med 5 kr. og gentager "hold"
4
Mandagens aktier: Dagens taber blev Bioporto i ellers positivt marked
5
Drilling/HSBC: Sænker kursmål med 43 kr. og gentager "køb"

Relaterede aktiekurser

Zealand Pharma A/S 146,40 -1,6% Fald i aktiekurs
Zealand Pharma Aktiesels.. 146,40 -1,6% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
16. juli 2019 02:09:08
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB5 - 2019-07-16 02:09:08 - 2019-07-16 02:09:08 - 1 - Website: OKAY